Themis Bioscience is a vaccine development company based in Vienna, Austria. The lead product is a vaccine against the tropical disease Chikungunya which is in late-stage clinical testing. In addition, Themis leveraged their vaccine platform technology to start developing a vaccine against Covid-19.
Themis Bioscience was acquired by MSD in May 2020.
YEAR OF INVESTMENT
2019
YEAR OF EXIT
2020
SECTOR
Vaccines
LOCATION
Vienna, Austria
WEBSITE
https://www.themisbio.com/